Evox appoints ex-GSK exec Martin Andrews as new non-Executive Director
Evox Therapeutics has named ex-GlaxoSmithKline executive Martin Andrews as its new non-Executive Director, it has emerged.
Andrews has previously served in commercial leadership and non-Executive Director roles and will bring his expertise in strategic development, vaccines, rare diseases and gene therapy to his new position.
He joins Evox from his previous role as Senior Vice President, Rare Diseases at GSK, where he held positions of increasing seniority. In the role, he led the company’s rare disease business, including the development of its portfolio of ex vivo gene therapies, and oversaw the transfer of this portfolio to Orchard Therapeutics.
He also served as GSK’s Senior Vice President, Global Vaccines Commercial prior to this, overseeing strategy and growth for its vaccines division.
Besides these roles, Andrews has also sat on the board of Orchard Therapeutics and the Alliance for Regenerative Medicine, and he is currently a non-Executive director at Freeline Therapeutics.
“We’re very pleased to welcome Martin as a non-Executive Director,” commented Evox CEO Dr Antonin de Fougerolles. “With his rare disease drug development experience and strong track-record of commercial success, Martin will be a great asset to the company. His expertise will play an important role in helping guide our business growth.”
Andrews himself remarked on his appointment: “I’m delighted to be joining the board of Evox. This is an exciting period for the company and I believe its technology has the potential to transform how medicines are developed and delivered for patients with conditions that are not possible to treat adequately today, especially those with rare diseases. I am thrilled to be part of the team and look forward to contributing.”
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …
GSK and Save the Children have announced that they will be renewing their partnership for …